An observational study on the efficacy of single injection of omalizumab in the treatment of chronic spontaneous urticaria

Clicks: 183
ID: 261731
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #18 of 18 articles by views in dermatologic therapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Chronic Spontaneous Urticaria (CSU) is one of the most challenging therapeutic problems faced by dermatologists. Omalizumab is a third line drug for CSU which is currently recommended as monthly injections for 6 months. To study the efficacy of single injection of Omalizumab in the treatment of CSU. …
Reference Key
s2020dermatologican Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lal Vijayalal S;Arora S;Dabas R;Janney MS;Jankal Basavarajappa S;Das NM;;
Journal dermatologic therapy
Year 2020
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/33040395
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:33040395 doi:10.1111/dth.14397 sandeep lal vijayalal sandeep arora niyor m das

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.